Gastroenterology
Volume 138, Issue 3 , Pages 854-869 , March 2010

History, Molecular Mechanisms, and Endoscopic Treatment of Barrett's Esophagus

  • Stuart Jon Spechler

      Affiliations

    • VA North Texas Healthcare System and The University of Texas Southwestern Medical Center, Dallas, Texas
    • Corresponding Author InformationReprint requests Address requests for reprints to: Stuart Jon Spechler, MD, Division of Gastroenterology, Dallas VA Medical Center, 4500 South Lancaster Road, Dallas, Texas 75216. fax: (214) 857-1571
    • ,
  • Rebecca C. Fitzgerald

      Affiliations

    • MRC Cancer Cell Unit, Hutchison-MRC Research Centre, Cambridge, England
    • ,
  • Ganapathy A. Prasad

      Affiliations

    • Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Kenneth K. Wang

      Affiliations

    • Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota

Received 3 December 2009 ,Accepted 11 January 2010.

References 

  1. Lord RV. Norman Barrett, “doyen of esophageal surgery”. Ann Surg. 1999;229:428–439
  2. Vakil N, van Zanten SV, Kahrilas P, et al. Global Consensus Group The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920
  3. Barrett NR. Chronic peptic ulcer of the oesophagus and “oesophagitis”. Br J Surg. 1950;38:175–182
  4. Tileston W. Peptic ulcer of the oesophagus. Am J Med Sci. 1906;132:240–265
  5. Allison PR, Johnstone AS. The oesophagus lined with gastric mucous membrane. Thorax. 1953;8:87–101
  6. Barrett NR. The lower esophagus lined by columnar epithelium. Surgery. 1957;41:881–894
  7. Hayward J. The lower end of the oesophagus. Thorax. 1961;16:36–41
  8. Bosher LH, Taylor FH. Heterotopic gastric mucosa in the esophagus with ulceration and stricture formation. J Thorac Surg. 1951;21:306–312
  9. Morson BC, Belcher JR. Adenocarcinoma of the esophagus and ectopic gastric mucosa. Br J Cancer. 1952;6:127–130
  10. Pedersen SA, Hage E, Nielsen PA, et al. Barrett's syndrome: morphological and physiological characteristics. Scand J Thorac Cardiovasc Surg. 1971;6:191–205
  11. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med. 1976;295:476–480
  12. Burgess JN, Payne WS, Andersen HA, et al. Barrett esophagus: the columnar-epithelial-lined lower esophagus. Mayo Clin Proc. 1971;46:728–734
  13. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition: report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg. 1975;70:826–834
  14. Borrie J, Goldwater L. Columnar cell-lined esophagus: assessment of etiology and treatment: a 22 year experience. J Thorac Cardiovasc Surg. 1976;71:825–834
  15. Skinner DB, Walther BC, Riddell RH, et al. Barrett's esophagus: comparison of benign and malignant cases. Ann Surg. 1983;198:554–565
  16. Adler RH. The lower esophagus lined by columnar epithelium: its association with hiatal hernia, ulcer, stricture, and tumor. J Thorac Cardiovasc Surg. 1963;45:13–32
  17. Hawe A, Payne WS, Weiland LH. Adenocarcinoma in the columnar epithelial lined lower (Barrett) esophagus. Thorax. 1973;28:511–514
  18. Haggitt RC, Tryzelaar J, Ellis FH, et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol. 1978;70:1–5
  19. Haggitt RC, Dean PJ. Adenocarcinoma in Barrett's epithelium. In:  Spechler SJ,  Goyal RK editor. Barrett's esophagus: pathophysiology, diagnosis, and management. New York: Elsevier; 1985;p. 153–166
  20. Reid BJ, Weinstein WM. Barrett's esophagus and adenocarcinoma. Annu Rev Med. 1987;38:477–492
  21. Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology. 1988;94:81–90
  22. Reid BJ. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. 1991;20:817–834
  23. Weinstein WM, Ippoliti AF. The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc. 1996;44:91–95
  24. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344:1533–1536
  25. Spechler SJ. The columnar lined oesophagus: a riddle wrapped in a mystery inside an enigma. Gut. 1997;41:710–711
  26. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677
  27. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831
  28. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus (The need for standardization of the definition and of endoscopic criteria). Am J Gastroenterol. 1998;93:1033–1036
  29. Riddell RH, Odze RD. Definition of Barrett's esophagus: time for a rethink—is intestinal metaplasia dead?. Am J Gastroenterol. 2009;104:2588–2594
  30. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut. 2006;55:442
  31. Chandrasoma P. Pathophysiology of Barrett's esophagus. Semin Thorac Cardiovasc Surg. 1997;9:270–278
  32. Liu W, Hahn H, Odze RD, et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol. 2009;104:816–824
  33. Hahn HP, Blount PL, Ayub K, et al. Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am J Surg Pathol. 2009 Apr 9;[Epub ahead of print]
  34. Takubo K, Aida J, Naomoto Y, et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol. 2009;40:65–74
  35. Kelty CJ, Gough MD, Van Wyk Q, et al. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol. 2007;42:1271–1274
  36. Gatenby PA, Ramus JR, Caygill CP, et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol. 2008;43:524–530
  37. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol. 1999;154:965–973
  38. Pera M, Pera M. Experimental Barrett's esophagus and the origin of intestinal metaplasia. Chest Surg Clin North Am. 2002;12:25–37
  39. Seery JP. Stem cells of the oesophageal epithelium. J Cell Sci. 2002;115:1783–1789
  40. Glickman JN, Chen YY, Wang HH, et al. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am J Surg Pathol. 2001;25:569–578
  41. Sarosi G, Brown G, Jaiswal K, et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus. 2008;21:43–50
  42. Hu Y, Williams VA, Gellersen O, et al. The pathogenesis of Barrett's esophagus: secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells. J Gastrointest Surg. 2007;11:827–834
  43. Kazumori H, Ishihara S, Kinoshita Y. Roles of caudal-related homeobox gene Cdx1 in oesophageal epithelial cells in Barrett's epithelium development. Gut. 2009;58:620–628
  44. Pera M, Pera M, de Bolos C, et al. Duodenal-content reflux into the esophagus leads to expression of Cdx2 and Muc2 in areas of squamous epithelium in rats. J Gastrointest Surg. 2007;11:869–874
  45. Wong NA, Wilding J, Bartlett S, et al. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci U S A. 2005;102:7565–7570
  46. Beck F. The role of Cdx genes in the mammalian gut. Gut. 2004;53:1394–1396
  47. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol. 2008;295:G211–G218
  48. Liu T, Zhang X, So CK, et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis. 2007;28:488–496
  49. Milano F, van Baal JW, Buttar NS, et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology. 2007;132:2412–2421
  50. Avissar NE, Toia L, Hu Y, et al. Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR). J Gastrointest Surg. 2009;13:212–222
  51. Clemons NJ, McColl KE, Fitzgerald RC. Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology. 2007;133:1198–1209
  52. Zhang HY, Hormi-Carver K, Zhang X, et al. In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double strand breaks. Cancer Res. 2009;69:9083–9089
  53. Jenkins GJ, D'Souza FR, Suzen SH, et al. Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: the potential role of anti-oxidants in Barrett's oesophagus. Carcinogenesis. 2007;28:136–142
  54. Jenkins GJ, Cronin J, Alhamdani A, et al. The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kappaB activation in oesophageal cells, with a mechanism of action involving ROS. Mutagenesis. 2008;23:399–405
  55. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus (An ex vivo proliferation and differentiation model). J Clin Invest. 1996;98:2120–2128
  56. Fitzgerald R, Omary M, Triadafilopoulos G. Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus. Am J Physiol. 1998;275:G47–G55
  57. Kaur BS, Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol. 2002;283:G327–G334
  58. Souza RF, Shewmake K, Pearson S, et al. Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol. 2004;287:G743–G748
  59. Hormi-Carver K, Zhang X, Zhang HY, et al. Unlike esophageal squamous cells, Barrett's epithelial cells resist apoptosis by activating the nuclear factor-kappaB pathway. Cancer Res. 2009;69:672–677
  60. Konturek PC, Nikiforuk A, Kania J, et al. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci. 2004;49:1075–1083
  61. Abdalla SI, Lao-Sirieix P, Novelli MR, et al. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res. 2004;10:4784–4792
  62. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut. 2002;50:451–459
  63. Shirvani V, Ouatu-Luscar R, Kaur B, et al. Cyclo-oxygenase 2 expression in Barrett's esophagus and adenocarcinoma (ex vivo induction by bile salts and acid exposure). Gastroenterology. 2000;118:487–496
  64. Capello A, Moons LM, Van de Winkel A, et al. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am J Gastroenterol. 2008;103:1510–1516
  65. Yen CJ, Izzo JG, Lee DF, et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res. 2008;68:2632–2640
  66. Kamat P, Wen S, Morris J, et al. Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis. Ann Thorac Surg. 2009;87:655–662
  67. Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130:883–890
  68. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008;53:2307–2312
  69. Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130:639–649
  70. Ryan AM, Healy LA, Power DG, et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg. 2008;247:909–915
  71. Watanabe S, Hojo M, Nagahara A. Metabolic syndrome and gastrointestinal diseases. J Gastroenterol. 2007;42:267–274
  72. Rubenstein JH, Dahlkemper A, Kao JY, et al. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol. 2008;103:1358–1364
  73. Suzuki H, Iijima K, Scobie G, et al. Nitrate and nitrosative chemistry within Barrett's oesophagus during acid reflux. Gut. 2005;54:1527–1535
  74. El-Serag HB, Lagergren J. Alcohol drinking and the risk of Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2009;136:1155–1157
  75. Chen X, Yang G, Ding WY, et al. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis. 1999;20:1801–1808
  76. Boult J, Roberts K, Brookes MJ, et al. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res. 2008;14:379–387
  77. Derakhshan MH, Liptrot S, Paul J, et al. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58:16–23
  78. Corley DA, Kubo A, Levin TR, et al. Hemochromatosis gene status as a risk factor for Barrett's esophagus. Dig Dis Sci. 2008;53:3095–3102
  79. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2006;55:1810–1820
  80. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer. 2003;3:676–684
  81. Maley CC, Galipeau PC, Li X, et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 2004;64:3414–3427
  82. Barrett MT, Sanchez CA, Neshat K, et al. Allelic loss of 9p21 and mutations of the CDKN2/p16 gene develop as early events in neoplastic progression in Barrett's esophagus. (abstr) Gastroenterology. 1996;110:A489
  83. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet. 1999;22:106–109
  84. Hardie LJ, Darnton SJ, Wallis YL, et al. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett. 2005;217:221–230
  85. Chao DL, Sanchez CA, Galipeau PC, et al. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res. 2008;14:6988–6995
  86. Galipeau PC, Li X, Longton G, et al. A panel of molecular and cytometric markers in Barrett's Oesophagus predicts progression to oesophageal adenocarcinoma. Gastroenterology. 2004;126:A114
  87. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 2001;61:8284–8289
  88. Lai LA, Paulson TG, Li X, et al. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer. 2007;46:532–542
  89. Huang Y, Peters CJ, Fitzgerald RC, et al. Progressive silencing of p14ARF in oesophageal adenocarcinoma. J Cell Mol Med. 2009;13:398–409
  90. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839–2848
  91. Murray L, Sedo A, Scott M, et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut. 2006;55:1390–1397
  92. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst. 2000;92:1316–1321
  93. Hong MK, Laskin WB, Herman BE, et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer. 1995;72:423–429
  94. Sirieix P, O'Donovan M, Brown J, et al. Surface expression of mini-chromosome maintenance proteins provides a novel method for detecting patients at risk for developing adeocarcinoma in Barrett's oesophagus. Clin Cancer Res. 2003;9:2560–2566
  95. Williams GH, Swinn R, Prevost AT, et al. Diagnosis of oesophageal cancer by detection of minichromosome maintenance 5 protein in gastric aspirates. Br J Cancer. 2004;91:714–719
  96. Lao-Sirieix PS, Brais RJ, Lovat LB, et al. Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis. Neoplasia. 2004;6:751–760
  97. Maley CC, Galipeau PC, Li X, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. 2004;64:7629–7633
  98. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 2005;6:945–952
  99. Chao DL, Maley CC, Wu X, et al. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:1935–1940
  100. Williams BR, Prabhu VR, Hunter KE, et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science. 2008;322:703–709
  101. Cestari R, Villanacci V, Rossi E, et al. Fluorescence in situ hybridization to evaluate dysplasia in Barrett's esophagus: a pilot study. Cancer Lett. 2007;251:278–287
  102. Chaves P, Crespo M, Ribeiro C, et al. Chromosomal analysis of Barrett's cells: demonstration of instability and detection of the metaplastic lineage involved. Mod Pathol. 2007;20:788–796
  103. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071–3083
  104. Galipeau PC, Prevo LJ, Sanchez CA, et al. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst. 1999;91:2087–2095
  105. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38:468–473
  106. Leedham SJ, Preston SL, McDonald SA, et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut. 2008;57:1041–1048
  107. Muzeau F, Flejou JF, Belghiti J, et al. Infrequent microsatellite instability in oesophageal cancers. Br J Cancer. 1997;75:1336–1339
  108. Brandt LJ, Kauvar DR. Laser-induced transient regression of Barrett's epithelium. Gastrointest Endosc. 1992;38:619–622
  109. Berenson MM, Johnson TD, Markowitz NR, et al. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology. 1993;104:1686–1691
  110. Curvers WL, Singh R, Song LM, et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut. 2008;57:167–172
  111. Fernando HC, Murthy SC, Hofstetter W, et al. The Society of Thoracic Surgeons practice guideline series: guidelines for the management of Barrett's esophagus with high-grade dysplasia. Ann Thorac Surg. 2009;87:1993–2002
  112. Das A, Singh V, Fleischer DE, et al. A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol. 2008;103:1340–1345
  113. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut. 2008;57:1200–1206
  114. Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology. 2009;137:815–823
  115. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–498
  116. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008;68:867–876
  117. Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology. 2009;136:2101–2114e1–6
  118. Sampliner RE. Endoscopic therapy for Barrett's esophagus. Clin Gastroenterol Hepatol. 2009;7:716–720
  119. Falk GW. Radiofrequency ablation of Barrett's esophagus: should everybody get it?. Gastroenterology. 2009;136:2399–2401
  120. Prasad G, Wang KK. Endoscopic mucosal resection: esophageal applications. Curr Treat Options Gastroenterol. 2005;8:41–49
  121. Seewald S, Ang TL, Gotoda T, et al. Total endoscopic resection of Barrett esophagus. Endoscopy. 2008;40:1016–1020
  122. Peters FP, Kara MA, Curvers WL, et al. Multiband mucosectomy for endoscopic resection of Barrett's esophagus: feasibility study with matched historical controls. Eur J Gastroenterol Hepatol. 2007;19:311–315
  123. Larghi A, Lightdale CJ, Ross AS, et al. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy. 2007;39:1086–1091
  124. Mino-Kenudson M, Hull MJ, Brown I, et al. EMR for Barrett's esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc. 2007;66:660–666quiz 767, 769
  125. Peters FP, Brakenhoff KP, Curvers WL, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest Endosc. 2008;67:604–609
  126. Prasad GA, Buttar NS, Wongkeesong LM, et al. Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol. 2007;102:2380–2386
  127. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–378
  128. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol. 2001;32:379–388
  129. Lewis JT, Wang KK, Abraham SC. Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for Barrett esophagus: implications for staging of adenocarcinoma. Am J Surg Pathol. 2008;32:566–571
  130. Stein HJ, Feith M, Bruecher BL, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg. 2005;242:566–573discussion 573–575
  131. Buskens CJ, Westerterp M, Lagarde SM, et al. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc. 2004;60:703–710
  132. Manner H, May A, Pech O, et al. Early Barrett's carcinoma with “low-risk” submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol. 2008;103:2589–2597
  133. Larghi A, Lightdale CJ, Memeo L, et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc. 2005;62:16–23
  134. Dulai GS, Jensen DM, Cortina G, et al. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc. 2005;61:232–240
  135. Sampliner RE, Faigel D, Fennerty MB, et al. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointest Endosc. 2001;53:554–558
  136. Mork H, Al-Taie O, Berlin F, et al. High recurrence rate of Barrett's epithelium during long-term follow-up after argon plasma coagulation. Scand J Gastroenterol. 2007;42:23–27
  137. Ragunath K, Krasner N, Raman VS, et al. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol. 2005;40:750–758
  138. Pereira-Lima JC, Busnello JV, Saul C, et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol. 2000;95:1661–1668
  139. Wang KK, Lutzke L, Borkenhagen L, et al. Photodynamic therapy for Barrett's esophagus: does light still have a role?. Endoscopy. 2008;40:1021–1025
  140. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007;66:460–468
  141. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2007;132:1226–1233
  142. Prasad GA, Wang KK, Buttar NS, et al. Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc. 2007;65:60–66
  143. Hage M, Siersema PD, van Dekken H, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut. 2004;53:785–790
  144. Peters F, Kara M, Rosmolen W, et al. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in Barrett esophagus after endoscopic resection. Endoscopy. 2005;37:418–424
  145. Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;65:185–195
  146. Dunkin BJ, Martinez J, Bejarano PA, et al. Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device. Surg Endosc. 2006;20:125–130
  147. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288
  148. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998;37:171–186
  149. Dumot JA, Greenwald BD. Argon plasma coagulation, bipolar cautery, and cryotherapy: ABC's of ablative techniques. Endoscopy. 2008;40:1026–1032
  150. Greenwald BD, Dumot JA, Horwhat JD, et al. Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus. Dis Esophagus. 2009 Jun 9;[Epub ahead of print]
  151. Canto MI, Gorospe EC, Shin EJ, et al. Carbon dioxide (CO2) cryotherapy is a safe and effective treatment of Barrett's esophagus (BE) with HGD/intramucosal carcinoma. Gastrointest Endosc. 2009;69:AB341
  152. Hornick JL, Mino-Kenudson M, Lauwers GY, et al. Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. Am J Gastroenterol. 2008;103:38–47
  153. Mino-Kenudson M, Ban S, Ohana M, et al. Buried dysplasia and early adenocarcinoma arising in Barrett esophagus after porfimer-photodynamic therapy. Am J Surg Pathol. 2007;31:403–409
  154. Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut. 2000;46:574–577
  155. Bronner MP, Overholt BF, Taylor SL, et al. ; International Photodynamic Therapy Group for High-Grade Dysplasia in Barrett's Esophagus (Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia). Gastroenterology. 2009;136:56–64
  156. Pouw RE, Gondrie JJ, Rygiel AM, et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett's esophagus containing neoplasia. Am J Gastroenterol. 2009;104:1366–1373
  157. Wang KK. Selecting treatment for Barrett's esophagus: no second chances to make a first impression. Clin Gastroenterol Hepatol. 2008;6:1181–1182
  158. Yachimski P, Nishioka NS, Richards E, et al. Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol. 2008;6:1206–1211
  159. Yachimski P, Puricelli WP, Nishioka NS. Patient predictors of histopathologic response after photodynamic therapy of Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc. 2009;69:205–212
  160. Yachimski P, Puricelli WP, Nishioka NS. Patient predictors of esophageal stricture development after photodynamic therapy. Clin Gastroenterol Hepatol. 2008;6:302–308
  161. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–1137
  162. Gondrie JJ, Seewald S, Pouw RE, et al. Stepwise radical endoscopic resection for complete removal of Barrett's esophagus with early neoplasia: an international multicenter study. Gastrointestinal Endoscopy. 2008;67:AB175
  163. Yoshinaga S, Gotoda T, Kusano C, et al. Clinical impact of endoscopic submucosal dissection for superficial adenocarcinoma located at the esophagogastric junction. Gastrointest Endosc. 2008;67:202–209
  164. Sharma P, Wani S, Weston AP, et al. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut. 2006;55:1233–1239
  165. Attwood SE, Lewis CJ, Caplin S, et al. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol. 2003;1:258–263
  166. Ferraris R, Fracchia M, Foti M, et al. Barrett's oesophagus: long-term follow-up after complete ablation with argon plasma coagulation and the factors that determine its recurrence. Aliment Pharmacol Ther. 2007;25:835–840
  167. Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc. 2005;62:24–30

 Conflicts of interest The authors disclose no conflicts.

 Funding This work was supported by the Office of Medical Research, Department of Veterans Affairs and the National Institutes of Health (R01-CA134571). Dr Spechler receives research support from AstraZeneca, Takeda Pharmaceuticals, Inc, and BARRX Medical, Inc. Dr Spechler is a consultant for Procter & Gamble and Xenoport. Dr Wang received NIH grants R01CA097048, R01CA111603, and R21CA122426. In addition, Dr Wang receives research support from Mayo Foundation, BARRX Medical, Inc, Axcan Pharma, Olympus and Fujinon. Dr Prasad receives research support from AstraZeneca, Takeda, and the Mayo Foundation. Dr Fitzgerald receives research support from the Medical Research Council (MRC).

PII: S0016-5085(10)00018-1

doi: 10.1053/j.gastro.2010.01.002

Gastroenterology
Volume 138, Issue 3 , Pages 854-869 , March 2010

Article Tools

* Image Usage & Resolution